Method and compositions for treating diseases mediated by transglutaminase activity

   
   

Diseases Mediated by transglutaminase, such as Huntington's Disease, spinobulbar atrophy, spinocerebellar ataxia, and dentatorubralpallidoluysian atrophy, as well as inflammatory diseases of the central nervous system, including mautiple sclerosis, rheumatoid arthritis, and insulin dependent diabetes mellitus, can be treated by administering a transglutaminase inhibitor such as monadansyl cadaverine, monoamines and diamines such as cystamine, putrescine, GABA. (gamma-amino benzoic acid), N-benzyloxy carbonyl, 5-deazp-4-oxonorvaline p-nitrophenylester, glycine methyl ester, CuSO4, and the oral anti-hyperglycemic agent tolbutamide.

Le malattie mediate dal transglutaminase, quale la malattia del Huntington, dal atrophy spinobulbar, dall'atassia spinocerebellar e dal atrophy dentatorubralpallidoluysian, come pure le malattie infiammatorie del sistema nervoso centrale, compreso la sclerosi del mautiple, dell'artrite rheumatoid e del mellitus dipendente del diabete dell'insulina, possono essere trattate amministrando un inibitore di transglutaminase quali la cadaverina, i monoamines e le diammine di monadansyl quali il cystamine, la putrescina, GABA. (acido benzoico gamma-amminico), il carbonilico di N-benzyloxy, il p-nitrophenylester 5-deazp-4-oxonorvaline, l'estere metilico della glicina, CuSO4 ed il tolbutamide anti-hyperglycemic orale dell'agente.

 
Web www.patentalert.com

< HBV capsid-binding peptide immunogens

< Viral recombinant vectors for expression in muscle cells

> Nasal delivery of parasiticides

> Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A

~ 00133